Results 41 to 50 of about 4,080 (215)

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ [PDF]

, 2021
Clinical treatment outcome of MRONJ (medication-related osteonecrosis of the jaw) surgery despite radical osseous removal and primary closure healing still shows differences in terms of outcome and disease recurrence. The study aims to assess the rate of
Mauceri, Rodolfo, Oteri, Giacomo, Ieni, Antonio, Antonia Marcianò, Giacomo Oteri, Antonio Ieni, Rodolfo Mauceri, Marcianò, Antonia   +7 more
core   +1 more source

The Efficacy of a Combined Medical and Surgical Protocol in the Management of Medication-Related Osteonecrosis of the Jaw: A Retrospective Study

Journal of Pharmacy and Bioallied Sciences
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious and debilitating condition characterized by exposed bone in the maxillofacial region in patients with a history of antiresorptive or antiangiogenic therapy.
Devang R. Deshpande, Harika Gadde, Lakshmi A. Gonuguntla, Devisri P. Peram, Joshi V Ram Dhara, Samreen I. Shaik   +5 more
doaj   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Evaluation of mandibular cortical bone ratio on computed tomography images in patients taking bisphosphonates

Maxillofacial Plastic and Reconstructive Surgery, 2018
Background Bisphosphonate (BP) has the ability to thicken the cortical bone. In addition, it has been reported that the cortical bone thickened by BP has relation to the medication-related osteonecrosis of the jaw (MRONJ).
Chul-Hong Koo, Jae-Hoon Lee
doaj   +1 more source

Romosozumab-associated medication-related osteonecrosis of the jaw

Oral and Maxillofacial Surgery Cases, 2023
This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin.
Benjamin Palla, John Anderson, Michael Miloro, Sarah Moles, Nicholas Callahan   +4 more
doaj   +1 more source

Medication-related osteonecrosis (MRONJ) of the mandible and maxilla

BMJ Case Reports, 2020
In 2003, Marx reported the first case of osteonecrosis of the jaw in 36 cases related to zoledronic acid or pamidronate. Painful bone exposure in the mandible or maxilla unresponsive to medical or surgical management was observed. In 2014, the American Association of Oral and Maxillofacial Surgeons proposed the term ‘medication-related osteonecrosis of
Dunphy L., Salzano G., Gerber B., Graystone J.   +3 more
openaire   +4 more sources

Systemic, Lifestyle and Environmental Modifying Factors in the Pathogenesis of Periodontitis

Journal of Periodontal Research, EarlyView.
A variety of impacting factors in the pathogenesis of periodontitis exist, including systemic, lifestyle, and environmental factors. This review highlights the manifold mechanistic aspects of the link between the pathogenesis of periodontitis, addressing these numerous factors to supplement the long‐standing knowledge of the progression of the disease.
Sabine Elisabeth Groeger, Yuxi Zhou, Jiawen Yong, Lei Wang, Sabine Ruf, Joerg Meyle   +5 more
wiley   +1 more source

Medication related osteonecrosis of the jaws (MRONJ): Diagnosis and treatment [PDF]

, 2020
This thesis aimed to provide more insight in the diagnosis of MRONJ and to study the best treatment for MRONJ. In order to give more insight in the different aspects of the diagnosis of MRONJ, part I focuses on origin, clinical and radiological features ...
Pichardo, S.E.C.
core  

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

Journal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag, Magdalena Mayol, Danijel Domic, Madhusudhan Reddy Bobbili, Johannes Grillari, Mariano Sanz, Reinhard Gruber   +6 more
wiley   +1 more source